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Abstract
Background: Vascular smooth muscle cell (VSMC) hyperplasia plays an important role in both
chronic and acute vascular pathologies including atherosclerosis and restenosis. Considerable work
has focused on the mechanisms regulating VSMC proliferation and motility. Earlier work in our lab
revealed a novel growth arrest-specific (gas) gene induced in VSMC exposed to the antiproliferative
agent heparin. This gene is a member of the CCN family and has been given the name CCN5. The
objective of the present study is to elucidate the function of CCN5 protein and to explore its
mechanism of action in VSMC.
Results: Using RNA interference (RNAi), we first demonstrate that CCN5 is required for the
antiproliferative effect of heparin in VSMC. We also use this gene knockdown approach to show
that CCN5 is an important negative regulator of motility. To explore the mechanism of action of
CCN5 on VSMC motility, we use RNAi to demonstrate that knock down of CCN5 up regulates
expression of matrix metalloproteinase-2 (MMP-2), an important stimulator of motility in VSMC.
In addition, forced expression of CCN5 via adenovirus results in reduced MMP-2 activity, this also
corroborates the gene knock down results. Finally, we show that loss of CCN5 expression in
VSMC causes changes in VSMC morphology and cytoskeletal organization, including a reduction in
the amount and macromolecular assembly of smooth muscle cell α-actin.
Conclusions: This work provides important new insights into the regulation of smooth muscle
cell proliferation and motility by CCN5 and may aid the development of therapies for vascular
diseases.
Background
Aberrant proliferation of smooth muscle cells (SMC) is
the hallmark of several pathological states, including arte-
riosclerosis, persistent pulmonary hypertension in the
newborn, pyloric stenosis, megaureter, and uterine
fibroids. Because vascular SMC (VSMC) hyperplasia is
responsible for the failure of a substantial fraction (as
high as 30%) of many vascular surgical procedures –
including percutaneous transluminal coronary angi-
oplasty, coronary artery bypass grafts, arterio-venous
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shunts, endarterectomies, and heart transplants – consid-
erable work has focused on the mechanisms regulating
VSMC hyperproliferation and on the search for agents that
can suppress VSMC mitogenesis. We and others have
studied the glycosaminoglycan heparin, which inhibits
VSMC proliferation and migration both in cell culture and
in animal models [1]. We recently described and charac-
terized a new member of the CCN family of growth factors
[2], CCN5, that is induced and maintained by heparin
treatment of VSMC and is expressed in a manner charac-
teristic of a growth arrest specific (gas) gene [3]. We have
also previously demonstrated that CCN5 is highly
expressed in the aorta, and carotid artery, and is dynami-
cally regulated upon vessel injury [3,4].
The CCN family members are secreted, cell- and matrix-
associated proteins that appear to play diverse and impor-
tant roles in cell function [5-9]. They have been impli-
cated in cell differentiation and survival, wound repair,
vascular disease, fibrosis, angiogenesis, and tumorigene-
sis. Due to their expression patterns, interactions with cell
surface proteins, and the ability to modulate cell func-
tions, members of the CCN family have also been
described as matricellular proteins [10]. All CCN proteins
contain 38 conserved cysteine residues and share a
homologous modular structure containing four distinct
domains, with the exception of CCN5, which lacks the
carboxy-terminal (CT) domain. Combined with its gas
gene expression pattern, this observation led us to
hypothesize that CCN5 plays a role in suppressing VSMC
proliferation and motility.
The CCN5 gene and protein have been described by us
and other laboratories and has been given a variety of
names (HICP [11], rCop-1 [12], Cop-1 [3], Wisp-2 [13]
and CTGF-L [14]). Homologues of CCN5 have been
found in cells from mice, rats, and human sources [8,9].
Results from studies in our laboratory have recently dem-
onstrated that overexpression of CCN5 protein has an
antiproliferative and antimotility effect on VSMC [4]. Ani-
mal models also revealed that CCN5 is expressed in a
manner consistent with control of smooth muscle cell
growth in intact and injured arteries [4]. Intact carotid
arteries show high levels of CCN5 expression in the
media, while balloon-injured tissues display loss of CCN5
expression. Expression only returns upon resolution of
the wound [4].
In the present study we examine the mechanism by which
CCN5 affects VSMC behavior, and offer evidence that
CCN5 mediates the antiproliferative effect of heparin on
VSMC.
Results
RNAi knocks down CCN5 levels in growth arrested VSMC
We have previously reported that overexpression of CCN5
in VSMC is able to inhibit proliferation and motility [4]
suggesting that this protein plays an important role in the
control of these processes. To more rigorously explore this
possibility and to understand the mechanism of CCN5 in
VSMC we employed RNA interference (RNAi) to knock
down endogenous CCN5 expression in these cells. siRNA
constructs designed to match nonconserved 21 nucleotide
sequences within the CCN5 mRNA were transfected into
VSMC. To determine the transfection efficiency of our
siRNA we used fluorescently tagged siRNA. The results
demonstrate that >90% of the VSMC contain siRNA after
transfection (Fig. 1A). Additionally, the level of fluores-
cent signal present in each individual cell does not signif-
icantly vary under our transfection conditions (Fig. 1A).
Real time quantitative PCR (Q-PCR) to detect levels of
CCN5 message in cDNA derived from VSMC reveal that
there is a significant decrease (77%) of CCN5 expression
in growth arrested cells treated with siRNA to target CCN5
message as compared to control siRNA treated cells (Fig.
1B). This decrease is similar to that seen in exponentially
growing VSMC, which show an 80% decrease in CCN5
levels when compared to untreated growth-arrested VSMC
(Fig. 1B).
To corroborate the Q-PCR analysis we carried out a West-
ern blot analysis to detect protein levels of CCN5 in
lysates from growth-arrested VSMC. We demonstrate a
significant (> 5-fold) decrease of CCN5 protein level in
CCN5 siRNA treated cells as compared to either untreated
or control siRNA treated cells (Fig. 1C). Taken together
with the results from the Q-PCR, these data demonstrate
that RNAi can efficiently and specifically reduce the
amount of CCN5 protein in growth-arrested VSMC. Fur-
thermore, they establish a valuable reagent and method
for studying the requirement of CCN5 in VSMC function
and for understanding its mechanism of action.
Knock down of CCN5 does not induce VSMC apoptosis in 
VSMC
It is possible that reduction of CCN5 levels in growth-
arrested VSMC could induce programmed cell death. To
test if RNAi knock down of CCN5 in VSMC altered apop-
tosis, we measured caspase-3 activity, as this enzyme is
generally activated in cells undergoing apoptosis (Fig. 2).
Caspase-3 activity was not elevated in lysates from
growth-arrested VSMC as compared to the untreated or
control siRNA treated cells (OD 0.035 vs. OD 0.017 and
0.035, Fig. 2). Positive and negative controls for caspase-3
activity were also included in the assay. Caspase-3 activity
was significantly elevated (OD 0.251) in lysates from pos-
itive control cells treated with staurosporine – a knownCell Communication and Signaling 2003, 1 http://www.biosignaling.com/content/1/1/5
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inducer of VSMC apoptosis [15]. This activity is com-
pletely blocked (OD 0.012) by an inhibitor specific to cas-
pase-3 (Fig. 2). These results establish that neither siRNA
treatment nor knockdown of CCN5 in VSMC induces
apoptosis in these cells.
Reducing CCN5 levels decreases heparin sensitivity of 
VSMC
Heparin has been previously shown to induce and main-
tain CCN5 expression in VSMC [3] and heparin also has a
well-established antiproliferative effect on VSMC [16,17].
Given our previous results demonstrating that CCN5 can
abrogate VSMC proliferation [4] we thought it important
to examine the role that CCN5 plays in the action of
heparin on smooth muscle. VSMC treated with RNAi to
knock down endogenous levels of CCN5 were tested for
their sensitivity to the antiproliferative effect of heparin.
Proliferation assays were performed on VSMC using a
range of heparin doses (10–300 µg/ml). The cells tested
were either untreated or transfected with siRNA. The con-
trol siRNA treated VSMC show no change in the 50%
effective dose (ED50) of heparin inhibition (~60 µg/ml,
Fig. 3) compared to the untreated cells (~60 µg/ml, Fig. 3).
The ED50 for heparin inhibition of VSMC treated with
CCN5 siRNA is ~5 fold greater than both controls (~300
µg/ml, Fig. 3). By using RNAi to knock down CCN5 we
have demonstrated that this protein can alter the antipro-
liferative effect of heparin in VSMC. This result also pro-
vides a potentially important link between the presence of
CCN5 in VSMC, and the antiproliferative effect of
heparin.
Characterization of CCN5 RNAi in VSMC Figure 1
Characterization of CCN5 RNAi in VSMC. A. VSMC 
transfected with fluorescein labeled siRNA and viewed live 
on an inverted fluorescent microscope to determine trans-
fection efficiency. B. Q-PCR results: Total cellular RNA was 
isolated from control and CCN5 RNAi treated VSMC. After 
reverse transcription they were subjected to Q-PCR analysis 
to assay CCN5 message level. Graph is representative of rel-
ative CCN5 levels in the various conditions. * indicates p < 
0.05 with respect to the value for expression in growth 
arrested cells. (AU = Arbitrary Units) C. Western blots 
depicting reduced CCN5 protein expression in CCN5 
siRNA treated VSMC. Top panel: Blot from cell lysates 
probed with anti-CCN5. Bottom Panel: Same blot 
stripped and reprobed with anti-GAPDH to insure equal 
loading. Lane1: untreated lysate Lane 2: control siRNA 
lysate Lane 3: CCN5 siRNA lysate.
CCN5 siRNA does not induce apoptosis in VSMC Figure 2
CCN5 siRNA does not induce apoptosis in VSMC. 2 × 
106 VSMC treated with siRNA were collected after overnight 
incubation in 10% FCS, washed in PBS, and then the lysates 
were assayed for caspase-3 activity. Exposure to stau-
rosporine at 2.5 µM in 10% FCS RPMI overnight was used as 
a positive control for apoptosis. Caspase-3 inhibitor was also 
added as a control to show that measured OD is due to cas-
pase-3 activity. Values have blank (OD 650 for reaction mix 
without substrate) subtracted. S = staurosporine, S+I = stau-
rosporine plus inhibitor.Cell Communication and Signaling 2003, 1 http://www.biosignaling.com/content/1/1/5
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Knock down of CCN5 increases motility of VSMC
VSMC migration from the media into the intimal surface
of the blood vessel is an important step during restenosis
following vascular surgical procedures. We have already
established that CCN5 overexpression can significantly
reduce motility of VSMC [4]. To ascertain whether CCN5
controls basal cell locomotion during G0 we have used
RNAi to knock down levels of the protein present in
growth arrested VSMC and observed the effect on cellular
motility and invasiveness in two independent assays.
Monolayer scratch wound assays have been used by our
laboratory and others to study VSMC motility [4,18,19].
In the case of the experiments presented here, the near
confluent VSMC were treated with siRNA, growth
arrested, and then wounded. The cells were kept in a state
of serum deprivation for the duration of the experiment.
The results therefore measure basal motility of the VSMC
in the normally non-motile state. We observed almost no
movement of cells into the wounded area in both
untreated and control siRNA treated monolayers (4 cells
and 6 cells respectively, Fig. 4A,4B), while CCN5 knock
down greatly increased wound coverage (123 cells, Fig.
4C).
VSMC in vivo must pass though the basement membrane
of the endothelial cell (EC) layer to enter the intimal sur-
face of the artery wall. To mimic the in vivo process and to
independently corroborate the scratch wound assay
results, we employed transwell chambers coated with
GFR-Matrigel, which may be thought of as a partially
reconstituted basement membrane. This method has been
used previously by our laboratory to show that CCN5
overexpression reduces the ability of VSMC to migrate
through a matrix environment [4]. Using this approach,
we now demonstrate that decreasing CCN5 levels in
growth-arrested VSMC can dramatically increase their
motility in response to a chemoattractant (10% FCS, Fig.
5). The filters from the untreated and control siRNA con-
ditions (Fig. 5A,5B) show significantly fewer cells have
entered the Matrigel and crossed the filter compared to the
CCN5 siRNA treated cells (Fig. 5C). VSMC with reduced
CCN5 levels (18.5 cells per field, Fig. 5D) exhibited a two-
fold increase in motility stimulated by 10% FCS as com-
pared to untreated and control VSMC (9 and 7.8 cells per
field respectively, Fig. 5D).
CCN5 regulates VSMC matrix metalloproteinase (MMP) 
expression
Taken together, the results of the scratch wound experi-
ment and the transwell assay just described demonstrate
that CCN5 is capable of regulating VSMC motility. The
following experiments were designed to explore the
mechanism of action of CCN5 on VSMC motility. We
examine the role of ECM modification, as well as
cytoskeletal reorganization as potential downstream effec-
tors of CCN5.
Matrix modification is a well-established requirement for
increased motility of VSMC and other cell types. For
example, MMPs are known to play an important role in
VSMC migration in vivo, contributing to arteriosclerosis,
and restenosis after balloon injury [20]. In addition, it has
already been shown that MMP-2 and 9 are required for
migration of VSMC through Matrigel in vitro [21,22]. To
determine whether or not the presence of CCN5 could
influence the expression of MMP-2 in VSMC we have
induced overexpression of CCN5 via adenovirus and also
knocked down CCN5 using RNAi. We then employed gel-
atin zymography to measure the level of MMP-2 released
by VSMC under various conditions.
Overexpression of CCN5, via adenovirus, reduces MMP-2
levels in conditioned medium taken from PDGF-BB
CCN5 RNAi reduces heparin sensitivity of VSMC Figure 3
CCN5 RNAi reduces heparin sensitivity of VSMC. 8 × 
103 VSMC/well, previously untreated or treated with control 
siRNA or CCN5 siRNA, were washed with RPMI and placed 
in RPMI containing 0.4% FCS for 72 h. Cells were released 
from quiescence by replacing the low serum medium with 
normal growth medium, RPMI-1640 containing 10% FCS. A 
range of heparin doses was added to the medium (10–300 
µg/ml). After 4 days of growth, cell proliferation was deter-
mined by direct cell counting using a Coulter Counter. The 
net growth of VSMC was obtained by subtracting the starting 
cell number from the final count results (at the time of 
release from G0).Cell Communication and Signaling 2003, 1 http://www.biosignaling.com/content/1/1/5
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stimulated VSMC (Fig. 6). While adenovirus infection
itself raises the level of total MMP-2 activity in growth
arrested cells (lane 1 vs. lane 4, Fig. 6), PDGF-BB raises
total MMP-2 levels in both controls (untreated and GFP
control infected) in a dose dependant manner (lanes 2–3
vs. lanes 5–6, Fig. 6). Conditioned medium from growth
arrested VSMC overexpressing CCN5 has the same
amount of total MMP-2 as GFP control conditioned
medium (lane 7 vs. lane 4, Fig. 6). Conditioned medium
from the CCN5 adenovirus infected cells that were treated
with PDGF-BB (lanes 8–9, Fig. 6) has approximately 3-
fold less total MMP-2 then GFP control conditioned
medium (lanes 5–6, Fig. 6).
Conversely, gelatin zymography indicates that knock
down of CCN5 in growth arrested VSMC increases the
level of MMP-2 produced (Fig. 7). Conditioned medium
from untreated (lane 1, Fig. 7) and control siRNA treated
cell (lane 2, Fig. 7) contain the same amount of total
MMP-2. In contrast, conditioned medium from CCN5
siRNA treated cells contain a 2-fold increase in total MMP-
2 (lane 3, Fig. 7) produced by the growth arrested VSMC.
This observation, combined with the forced expression
data, indicates that levels of CCN5 present in VSMC can
modulate the amount of MMP-2 produced. High CCN5
levels down-regulate MMP-2 production, whereas low
levels of CCN5 in VSMC permit up-regulation of MMP-2.
Knock down of CCN5 alters VSMC morphology
Confluent monolayers of growth-arrested VSMC display
the classic "hill and valley" morphology, which is charac-
terized by intertwined and overlapping bipolar cells (Fig.
4A and 8A). Treatment with control siRNA does not sig-
nificantly change this morphology (Fig. 4B and 8B), while
CCN5 knock down does (Fig. 4C and 8C). CCN5 siRNA
treated cells have a spread epithelial-like appearance in
contrast to that of untreated VSMC (Fig. 8C). This phe-
nomenon could explain, at least in part, the results we
observed in the scratch wound assay, and is also sugges-
tive of changes in VSMC cytoskeletal arrangement.
CCN5 may regulate the α-actin cytoskeleton
Growth arrested VSMC in culture normally produce rela-
tively high amounts of smooth muscle α-actin arranged in
a well-organized cytoskeleton (Fig 9A). It is possible that
CCN5 could be involved in the maintenance of stable α-
actin cytoskeleton in VSMC. Changes in cytoskeletal
organization could also account for the changes in cellular
motility and morphology we observe when CCN5 is
knocked down with RNAi. We therefore examined α-actin
location (Fig. 9) and mRNA expression (Fig. 10) in
growth-arrested, siRNA treated VSMC to determine if
reduced CCN5 levels could affect changes in cytoskeletal
arrangement and/or production. The results demonstrate
that CCN5 siRNA treated VSMC lack the prominent well-
organized stress fibers observed in untreated VSMC (Fig.
9A,9B). Q-PCR analysis of α-actin message expression in
CCN5 targeted siRNA promotes motility in growth arrested VSMC Figure 4
CCN5 targeted siRNA promotes motility in growth arrested VSMC. VSMC were plated at near confluence on glass 
chamber slides and then transfected overnight with 600 ng of siRNA to knockdown CCN5 levels or transfected with control 
siRNA. Following transfection VSMC were growth arrested by serum starvation for 72 hours. The confluent monolayers were 
then scratched uniformly with a pipette tip, excess cells were washed away, and serum free growth medium was added back. 
Initial pictures of the scratches were taken for reference (demarcation of initial wounds is represented by the white lines in 
each panel). The monolayers were then incubated for 48 hours at 37°C, fixed, stained with Diff-Quik to visualize cells and the 
extent of cell movement into the wound was measured by counting nuclei. The numbers below the panels represent the 
number of cells that have migrated into the wound area.Cell Communication and Signaling 2003, 1 http://www.biosignaling.com/content/1/1/5
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VSMC GFR-Matrigel transwell assay Figure 5
VSMC GFR-Matrigel transwell assay. VSMC previously untreated or treated with control or CCN5 siRNA (3 × 104 cells 
per well in 500 µl) were plated into the upper portion of GFR-Matrigel chambers (BD Biosciences) and allowed to invade for 
30 hours in response to 10% FCS. Filters were cleaned, fixed, stained, and counted as described in Experimental Procedures. 
Pictures are of representative stained filters photographed at low power under a dissecting microscope A. Untreated VSMC 
B. Control siRNA treated VSMC C. CCN5 siRNA treated VSMC. D. Graph representing quantitation of the results from 4 
fields on triplicate filters. * indicates p < 0.05 with respect to the value for untreated VSMC.Cell Communication and Signaling 2003, 1 http://www.biosignaling.com/content/1/1/5
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PDGF-induced MMP production is reduced in AdCCN5-infected cells Figure 6
PDGF-induced MMP production is reduced in AdCCN5-infected cells. Uninfected VSMC or VSMC infected with 
AdCCN5 or AdGFP were growth arrested by serum starvation for 72 h, and then treated overnight with serum-free medium 
containing the indicated concentrations of PDGF-AB. Conditioned media were collected, concentrated, and run on an SDS-
PAGE gelatin zymogram. The gel was stained with Coomassie Blue. The bands lacking stain indicate MMP activity. Upper band 
is MMP9 (Gelatinase B); lower bands are MMP2 (Gelatinase A) in both active (lower) and inactive (upper) forms as shown. Ad 
= Adenovirus.
CCN5 knock down increases MMP-2 expression in growth-arrested VSMC Figure 7
CCN5 knock down increases MMP-2 expression in growth-arrested VSMC. Untreated, control siRNA, or CCN5 
siRNA treated VSMC were growth arrested by serum starvation for 72 hr. Conditioned media were collected, concentrated, 
and run on an SDS-PAGE gelatin zymogram. The gel was stained with Coomassie Blue. The bands lacking stain indicate MMP 
activity. Bands are MMP2 (Gelatinase A) in both active (lower) and inactive (upper) forms as shown.
CCN5 knock down alters VSMC morphology Figure 8
CCN5 knock down alters VSMC morphology. Untreated, control siRNA, or CCN5 siRNA treated VSMC were growth 
arrested by serum starvation for 72 hr. Cells were then placed in serum free RPMI 1640 medium for 48 hours, fixed and 
stained with Diff-Quik to visualize morphology. A. Untreated B. Control siRNA treated C. CCN5 siRNA treated.Cell Communication and Signaling 2003, 1 http://www.biosignaling.com/content/1/1/5
Page 8 of 13
(page number not for citation purposes)
these cells indicates that CCN5 siRNA treated cells have
only half as much α-actin mRNA (0.9, Fig. 10) when com-
pared to untreated and control siRNA-treated VSMC (1.7
and 1.8, Fig. 10). Both of these results suggest that CCN5
is important to normal production and arrangement of
VSMC α-actin cytoskeleton.
Conclusions
In this study we report several novel observations on the
functions and possible mechanism of action of CCN5, a
member of the CCN family of matricellular proteins. We
demonstrate that CCN5 is necessary for the antiprolifera-
tive effect of heparin on VSMC in culture (Fig. 3). We pro-
vide functional evidence that CCN5 plays an important
role in the control of VSMC motility (Fig. 4, 5). Finally, we
offer insight into the mechanism of action of CCN5 on
VSMC by showing that this protein can control the expres-
sion of MMP-2 (Fig. 6, 7) and may also play an important
role in control of cell morphology (Fig. 8) and the organ-
ization of the actin cytoskeleton (Fig. 9, 10).
To examine the requirement for CCN5 protein in cell
function, we have established the use of RNAi to signifi-
cantly (5-fold) knock down expression of this protein in
growth-arrested VSMC (Fig. 1). Our group has previously
established CCN5 as a gas gene in these cells [3]. VSMC in
vivo also maintain a quiescent state and express high levels
of CCN5 [4]. Importantly, by using the RNAi technique,
levels of the protein can be lowered in growth-arrested
cells to the level observed in exponentially growing
VSMC. We have used this tool to understand the require-
ment for CCN5 in maintaining the characteristics of
growth arrested VSMC, such as sensitivity to heparin's
antiproliferative effect, low rate of motility, and a well
organized actin cytoskeleton.
Our data provides strong evidence that CCN5 mediates, at
least in part, the antiproliferative effect of heparin on
VSMC (Fig. 3). The negative effect of heparin on VSMC
mitogenesis has been known for more than two decades;
however, the mechanism of action is still unclear. While it
is likely that heparin has multiple modes of action in
VSMC, induction of CCN5 appears to be a major contrib-
utor to its antiproliferative effect.
Using two independent approaches, we have shown that
knock down of CCN5 levels in growth-arrested VSMC
leads to increased motility (Fig. 4, 5). We had previously
shown that the opposite is true for CCN5 overexpression
in VSMC [4]. Taken together these results demonstrate
that CCN5 is a negative regulator of VSMC motility and
invasiveness. Since we already know that relatively high
levels of CCN5 are present in quiescent VSMC residing in
the arterial media in vivo [3,4], it is tempting to speculate
CCN5 knockdown alters α-actin cytoskeleton Figure 9
CCN5 knockdown alters α-actin cytoskeleton. Untreated or CCN5 siRNA treated VSMC were growth arrested by 
serum starvation for 72 hr. Cells were then fixed and stained for α-actin (anti-α-actin mouse monoclonal antibody), secondary 
(Alexa-488-conjugated anti-mouse antibody; green), and nuclei (Hoechst stain; blue). A. Untreated VSMC. B. CCN5 siRNA 
treated VSMCCell Communication and Signaling 2003, 1 http://www.biosignaling.com/content/1/1/5
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that CCN5 could be responsible, at least in part, for main-
taining their non-motile, non-proliferative state. Lending
support to this hypothesis, results from the current study
demonstrate that the expression of MMP-2 in VSMC is
inversely correlated with expression of CCN5 (Fig. 6, 7).
MMPs are necessary for VSMC invasion during in vitro
assays [23,24], and MMP-2 is known to play an important
role in atherosclerotic plaque formation and restenosis
after vessel injury [25-28]. Interestingly, another family
member, CCN2, which is known to have a pro-motility
effect on VSMC [29], has also been shown to increase
MMP-2 expression in VSMC [30] and decrease levels of
tissue inhibitor of MMP-1 (TIMP-1) [31]. This is especially
intriguing because CCN2 is not found at high levels in
healthy aorta, but is up regulated 50–100 fold in athero-
sclerotic blood vessels [32]. In contrast, we observe high
levels of CCN5 in healthy rat arterial tissue [3,4] and
expression of CCN5 is abolished during restenosis follow-
ing balloon injury [4].
Our results suggest that CCN5 may play a role in the con-
trol of VSMC morphology and regulation of the cytoskel-
eton (Fig. 8, 9, 10). These changes in morphology and
cytoskeletal arrangement are consistent with the modula-
tion of motility observed. Indirect evidence demonstrates
that other CCN proteins possess the ability to alter
cytoskeleton of cells. Another CCN family member,
CCN2, was recently shown to influence cytoskeletal
arrangement in mesangial cells, [33] a cell type closely
related to VSMC. CCN1 and CCN2 both appear to act
through integrins [7]. These transmembrane receptors are
responsible for ECM binding on the outside and make
connections with the actin cytoskeleton in the cytoplasm
[34]. Integrins are central to the formation of focal adhe-
sion complexes, which are an integral part of stress fiber
formation within cells [34]. It is tempting to speculate that
CCN5 could help to stabilize these complexes, and exper-
iments to test this idea are underway. As discussed above,
these CCN family member proteins are both known to
stimulate motility in various cell types including VSMC
[8]. Additionally, CCN4, a protein capable of inhibiting
invasion and motility of tumor cells both in vivo as well as
in vitro, inhibits Rac activation [35], which is thought to be
intimately involved in regulation of cytoskeletal organiza-
tion [35].
In this study we provide functional data that CCN5 is
capable of inhibiting processes in cultured VSMC that are
thought to be important in the pathogenesis of arterio-
sclerosis and restenosis: motility and matrix modification.
We also provide evidence that CCN5 mediates the anti-
proliferative effect of heparin on VSMC. We also provide
data suggesting that CCN5 is important for the mainte-
nance of normal VSMC morphology and α-actin expres-
sion. While it is clear that the biological functions as well
as the pathophysiologic roles, if any, for CCN5 are com-
plex and likely to be tissue-specific, these data, taken
together with results from our previous studies [4], sug-
gest a role for CCN5 in the control of VSMC motility and
proliferation in both the healthy and injured artery wall.
Experiments to examine this possibility are currently
underway and should help shed light on the role of CCN5
in VSMC in vivo.
Methods
Materials
All tissue culture plastic ware, including growth factor
reduced (GFR)-Matrigel chambers, were obtained from
BD Biosciences (Lincoln Park, NJ). 8 µm polycarbonate
filter membranes for use in modified Boyden assays were
purchased from NeuroProbe Inc. (Cabin John, MD). Pre-
mium fetal calf serum (FCS) was purchased from
HyClone (Logan, UT). RPMI base media, trypsin-EDTA,
glutamine, and penicillin-streptomycin were purchased
from Gibco Life Technologies (Grand Island, NY).
Heparin, obtained from Glycomed (Alameda, CA) was
derived from porcine mucosa (sodium salt; average
molecular mass, 15 kDa). Pre-cast SDS-gels and running
system were obtained from Bio-Rad (Hercules, CA). ECL
CCN5 knockdown reduces VSMC α-actin expression Figure 10
CCN5 knockdown reduces VSMC α-actin expression. 
Total cellular RNA was isolated from control and CCN5 
RNAi treated VSMC. After reverse transcription they were 
subjected to Q-PCR analysis to assay α-actin message level. 
Graph is representative of relative α-actin levels in the 3 
conditions. * indicates p < 0.05 with respect to the value for 
untreated VSMC. (AU = Arbitrary Units)Cell Communication and Signaling 2003, 1 http://www.biosignaling.com/content/1/1/5
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Renaissance kit was purchased from New England
Nuclear (Boston, MA). Anti-CCN5 affinity-purified rabbit
polyclonal antibody was obtained from FibroGen (San
Francisco, CA). HRP and alexa-488-conjugated anti-rabbit
secondary antibodies were purchased from Jackson
ImmunoResearch Laboratories Inc. (West Grove, PA) and
Molecular Probes (Eugene, OR) respectively. All other
chemicals and reagents were purchased from Sigma (St.
Louis, MO).
Cell Culture
Primary cell cultures
Aortic muscle cells (VSMC) were obtained from aortae of
Sprague-Dawley rats (Charles River Breeding Laborato-
ries, Inc. Wilmington, MA). They were isolated, cultured,
and characterized as previously described [36]. Briefly, the
abdominal segment of the aorta was removed and the fas-
cia cleaned away under a dissecting microscope. The aorta
was cut longitudinally, and small pieces of the media were
carefully stripped from the vessel wall. Two or three such
strips were placed in 60 mm dishes. Within 1–2 weeks,
VSMC migrated from the explants; they were capable of
being passaged approximately 1 week after the first
appearance of cells. They were identified as VSMC by their
characteristic hill-and-valley growth pattern and indirect
immunofluorescence staining for VSMC specific α-actin.
All cultures were maintained in RPMI-1640 medium
containing 10% FCS (10% FCS/RPMI) at 37°C in a
humidified, 5% CO2/95% air atmosphere.
Growth arrest of cells
Cells were routinely plated at various densities, washed
with serum-free RPMI and placed in 0.4% FCS/RPMI for
72 h. Flow cytometry and determination of [3H] thymi-
dine-labeled nuclei indicated that greater than 95% of the
cells were arrested in G0(G1) [37]. Cells were released
from quiescence by replacing the low serum medium with
10% FCS/RPMI. Cultures were used at passage 8 or lower.
RNAi production and Transfection
Production of siRNA
CCN5 targeted 21 nucleotide siRNA was produced using
the Silencer siRNA in vitro transcription kit (Ambion, Aus-
tin, TX). The targeted sequence resides within the open
reading frame of the CCN5 mRNA, 306 nucleotides
downstream of the start codon. The method of Tuschl et.
al. [38] was used to determine the target sequence. The
sequence is as follows: aatggccgcaggtacctggat GAPDH tar-
geted siRNA, was also produced for use as a positive con-
trol for message knockdown, and also for transfection
condition optimization. Negative control siRNA, a 21-
nucleotide RNA duplex with no known sequence homol-
ogy, was also purchased from Ambion.
Production of fluorescent-tagged siRNA
Fluorescein labeled siRNA used to detect transfection effi-
ciency was produced with the Silencer Fluorescein siRNA
Labeling Kit from Ambion (Austin, TX). Negative control
siRNA was labeled using the kit. This siRNA was then
transfected into VSMC as described below. Cells were then
visualized and digital images were obtained with a RT
Color Spot camera (Diagnostic Instruments Inc.) on a
Nikon inverted fluorescence microscope. Figures were
prepared with Adobe Photoshop v. 6.0.
Transfection of siRNA
Transfection of siRNA into VSMC was achieved by using
the GeneSilencer siRNA Transfection Reagent, produced
by Gene Therapy Systems (San Diego, California). Briefly,
VSMC were plated overnight to achieve 50–70% conflu-
ent monolayers. siRNA and transfection reagent complex
was added to the cells in 10% serum containing medium
and incubated 24 hours at 37°C. Cells were then washed
with 10% serum containing medium for 1 hour and then
growth arrested for 72 hours as described above.
RNA analysis
mRNA collection and reverse transcription
Total cellular RNA from the various conditions described
above was harvested from 100 mm culture dishes as fol-
lows. Monolayers were rinsed twice with phosphate buff-
ered saline (PBS, pH 7.6) and RNA was collected using the
RNeasy Mini kit (QIAGEN, Valencia, CA). Contaminating
DNA was removed using the DNA-free kit (Ambion, Aus-
tin, TX), and reverse transcription was performed using
the RETROscript kit (Ambion, Austin, TX). All assays were
performed according to the manufacturer's protocol. Con-
trols containing no reverse transcriptase were used to
check for genomic DNA contamination in each sample.
PCR using the HotStarTaq kit (QIAGEN, Valencia, CA)
and examination of products on a 1.8% agarose gel con-
firmed the absence of genomic DNA.
Real time Quantitative PCR
Primers were purchased from IDT (Coralville, IA). The
sense CCN5 (GenBank accession number gi 7739780)
primer was 5'-CACCAACTTTCTGCCCTTGT-3' (position
796–815), and the antisense CCN5 primer was 5'-ATCTC-
CAGTTGGCAGAATCG-3' (position 922–941). These
primers produced a product size of 146. The sense
GAPDH (GenBank accession number gi 8393417) primer
was 5'-GAAGGGCTCATGACCACAGT-3' (position 538–
557), and the antisense GAPDH primer was 5'-GGAT-
GCAGGGATGATGTTCT-3' (position 635–654), produc-
ing a product size of 117. Real-time PCR was performed
using SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA). The reactions were performed on the
GeneAmp 5700 Sequence Detection System (PE Applied
Biosystems, Foster City, CA). No template and no reverseCell Communication and Signaling 2003, 1 http://www.biosignaling.com/content/1/1/5
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transcriptase samples were used as controls. The cycling
conditions were: 95°C 10 min, and 40 cycles of 95°C 15
s and 60°C 1 min. The standard dissociation protocol was
performed to confirm the absence of primer dimers, and
product size was determined by running PCR products on
a 1.8% agarose gel. A standard curve (Ct vs. log C0) was
constructed using a dilution series of rat lung total RNA
(Ambion, Austin, TX) transcribed to cDNA using the same
protocol outlined above, and relative amounts of CCN5
and GAPDH were determined.
Adenovirus production and infection
An adenovirus expressing both Green Fluorescent Protein
(GFP) and CCN5 tagged by a nine amino acid HA epitope
on the C-terminus, was produced using the Ad-Easy sys-
tem provided and described by He et al. (1998). This virus
has been described in more detail previously [4]
VSMC are routinely infected in our laboratory by the fol-
lowing method. Cells are first washed and exposed to var-
ious amounts of virus for 2 hours in serum free RPMI-
1640 with occasional agitation. 10% FCS/RPMI contain-
ing medium is then added back to the cells. After 1–2 days
infected cells can be trypsinized and used for experiments
as usual. Infection can be monitored quickly by observing
the fraction of cells expressing GFP in the population. It
has been previously demonstrated in our lab that the
AdCCN5 used induces overexpression of CCN5 adjusta-
ble over a range of moi [4].
Protein analysis
Western Blotting
Proteins from the various conditions described above
were harvested from 100 mm culture dishes as follows,
with all procedures performed at 4°C. Cells were rinsed
twice with cold TBS (20 mmol/L Tris, pH 7.6, 137 mmol/
L NaCl) and lysed with 100 µl of RIPA lysis buffer. Lysates
were transferred to Eppendorf tubes, rocked for 20 min
and spun at 12,000 rpm for 10 min in an Eppendorf
microfuge (Hamburg, Germany). Supernatant was stored
at negative 20°C until use. Protein estimations were per-
formed using the Pierce BCA method adapted for micro-
titer plates. Extracts containing from 10–40 µg of protein
were boiled in 2X SDS sample loading buffer, resolved by
SDS-PAGE (either 10% or 4→20% gradient gels were
used), and blotted onto 0.2 µm pore size Immun-Blot
PVDF membranes (Bio-Rad, Hercules, CA) in Towbin
buffer without methanol (25 mmol/L Trizma base, 192
mmol/L glycine) at 200 mA for five h. The blots were
dried and rewetted. Membranes were blocked for 1 h in
TBS containing 5% milk and Western blots were per-
formed using primary antibodies described above (1:500)
and HRP-conjugated anti-rat or anti-rabbit IgG
(1:10,000) in TBST (TBS + 0.2% Tween 20). Bands were
visualized using the NEN (Boston, MA) Renaissance
enhanced chemiluminescence (ECL) detection reagents
and autoradiography as described by the vendor. Pre-
stained protein standard markers (BioRad) were used as
molecular weight markers. Densitometry analysis of films
was performed using the Stratagene (La Jolla, CA) Eagle
Eye II system. Blots were stained with Amido Black stain
to confirm equal loading and proper transfer of proteins
to the membrane.
Immunocytochemistry
VSMC were plated onto 18 mm cover slips in 24-well
dishes at a density of 8 × 103 cells/well. Cells were growth
arrested and subsequently reintroduced to normal growth
medium for various times. Cover slips were then fixed and
blocked as described above, followed by exposure to the
affinity-purified rabbit anti-peptide antibody specific to
CCN5 or a mouse monoclonal antibody specific to
smooth muscle α-actin. Secondary antibody, goat anti-
mouse conjugated to alexa-488 (Molecular Probes,
Eugene, OR) was used to visualize smooth muscle α-actin
in the cells. Hoechst 33258 stain was also added to the
mounting medium in order to visualize cell nuclei. Digital
images were obtained with a RT Color Spot camera (Diag-
nostic Instruments Inc.) on a Nikon inverted fluorescence
microscope. Figures were prepared with Adobe Pho-
toshop v. 6.0.
Gelatin Zymography
Conditioned medium from growth arrested cells was
loaded into in precast 10% acrylamide gels impregnated
with gelatin (Biorad, Hercules, CA) and subjected to SDS-
PAGE electrophoresis. Gels were then renatured (2.5%
Triton X-100), developed overnight (50 mM Tris, pH 7.6,
10 mM CaCl2), and stained with Commassie blue for 1
hour (0.5% Coomassie blue, 30% isopropanol, 10% ace-
tic acid). After destaining (10% isopropanol 1 hour fol-
lowed by water to allow gel to swell to normal size), gels
were photographed using the Stratagene (La Jolla, CA)
Eagle Eye II system.
Cell proliferation assay
Cell proliferation assays were performed as described pre-
viously [39]. Briefly, 8 × 103 cells were plated into 16 mm
multiwell dishes. In some cases, cells were previously
transfected with siRNA as described above. Cells were
then growth arrested as above. Cultures were released
from G0 by exposure to 10% FCS/RPMI. In some cases
cells were also treated with 10% FCS/RPMI containing a
range of 10–300 µg/ml heparin. Cells were allowed to
grow for the indicated time and then counted in duplicate
after trypsinization using a Coulter counter (Fullerton,
CA). The net growth of VSMC was obtained by subtracting
the starting cell number from the above count results (at
the time of release from G0). Experimental conditionsCell Communication and Signaling 2003, 1 http://www.biosignaling.com/content/1/1/5
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were performed in triplicate on two separate occasions.
Degree of inhibition is determined as follows:
Cell motility
Scratch wound motility assay:[18,19]
siRNA transfected VSMC were plated at confluence onto
glass chamber slides. The following day a uniform straight
scratch was made in the monolayer using a 200 µl yellow
plastic pipet tip (Fisher). Monolayers were washed gently,
marked (for reference) and photographed using Nomar-
ski optics on an inverted microscope. After incubation for
30 h at 37°C, the cells were fixed in 1% paraformaldehyde
and mounted. Cells were stained using the Diff-Quik stain
set (Dade Behring Inc., Newark, DE). Calculations are
based on the number of nuclei that have moved into the
wound area. Four counts were made at various points
along each wound that were photographed initially and
marked. Cell numbers are derived from the average of
these fields from triplicate samples.
GFR-Matrigel transwell chamber assay:[21,25,28]
VSMC motility through matrix was measured using cham-
bers (BD Biosciences, New Bedford, MA) containing an 8
µm pore size polycarbonate filter insert that divides the
chamber into upper and lower portions. The filters were
either uncoated or uniformly coated with GFR-Matrigel.
We used the protocol provided by the supplier. Briefly, 3
× 104 cells were added to the upper chamber of the insert
while 10% FCS was added in RPMI-1640 to the lower
chambers. After allowing the assay to proceed for 32 h,
cells on the top of the filter were removed by gentle swab-
bing and the remaining cells on the bottom side of the fil-
ter were stained using Diff-Quik (Dade Behring Inc.,
Newark, DE), and counted under a light microscope with
an eyepiece grid to visualize set fields. At least 4 fields in
triplicate wells were counted for each condition.
Detection of apoptosis
The ApoAlert Caspase-3 Colorimetric Assay Kit by Clon-
tech (Palo Alto, CA) was used according to the manufac-
turer's instructions to determine the amount of apoptosis
in VSMC cultures. Briefly, 2 × 106  AdGFP-infected,
AdCCN5-infected, or uninfected control cells were col-
lected after overnight incubation in 10% FCS, washed in
PBS, and then the lysates were assayed for caspase-3 activ-
ity. Exposure to staurosporine at 2.5 µM in 10% FCS/
RPMI overnight was used as a positive control for apopto-
sis [15].
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